None
Conditions
Interventions
Propofol group:Anesthesia induction: propofol 2.0-2.5mg /kg was slowly injected intravenously within 1 min
Anesthesia maintenance: The dosage of propofol was 4-10 mg/kg/h, and adjusted appropriately according to the general condition of the individual subject until the end of surgery
Remazolam toluenesulfonate group:nesthesia induction: intravenous injection of Remazolam toluenesulfonic 0.2-0.3mg /kg
Anesthesia maintenance: Remazolam toluenesulfonate was pumped intravenously at a dose of 0.5-1 mg/kg/h, adjusted according to the general condition of the individual subject (maximum allowable pumping
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
19 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1.Day surgery to be performed under endotracheal intubation under general anesthesia; 2.Aged 18 to 60 years; 3.American anesthesiologist grade (ASA) I or II; 4.18 kg/m^2 < BMI < 28 kg/m^2; 5.Volunteer to participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients with known allergy to benzodiazepines or with a previous history of severe allergy and a family history; 2.Long-term use of narcotic analgesics, sedatives or non-steroidal anti-inflammatory drugs; 3.Previous history of schizophrenia, epilepsy, Parkinson's disease or myasthenia gravis; 4.Unable to communicate due to severe dementia or language barrier before surgery; 5.Severe renal function impairment (requiring renal replacement therapy); Severe liver function impairment (Child-Pugh grade C); 6.Bradycardia, heart rate =90 min; 9.Vulnerable groups, including mental illness, critically ill patients, pregnant women, minors, cognitive impairment, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| sedative effectiveness;respiratory rate;haemodynamics;Intraoperative awakening or awareness;sedative remedy;limb activity;rimazolam dosage;arrhythmia;intraoperative infusion velocity changes and corresponding time points;recovery quality;other indicators;hepatorenal function;cognitive function;adverse event;pain, nausea and vomiting;satisfaction evaluation; | — |
Countries
China
Contacts
Public ContactChen Gang
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Outcome results
None listed